AU2001248314A1 - Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens - Google Patents

Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens

Info

Publication number
AU2001248314A1
AU2001248314A1 AU2001248314A AU2001248314A AU2001248314A1 AU 2001248314 A1 AU2001248314 A1 AU 2001248314A1 AU 2001248314 A AU2001248314 A AU 2001248314A AU 2001248314 A AU2001248314 A AU 2001248314A AU 2001248314 A1 AU2001248314 A1 AU 2001248314A1
Authority
AU
Australia
Prior art keywords
pseudomonas
heterologous antigens
natural adjuvant
inducing natural
oprl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001248314A
Other versions
AU2001248314B2 (en
Inventor
Pierre Cornelis
Patrick De Baetselier
Hilde Revets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Priority claimed from PCT/EP2001/001673 external-priority patent/WO2001060404A2/en
Publication of AU2001248314A1 publication Critical patent/AU2001248314A1/en
Application granted granted Critical
Publication of AU2001248314B2 publication Critical patent/AU2001248314B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001248314A 2000-02-18 2001-02-13 Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens Ceased AU2001248314B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200589.0 2000-02-18
EP00200589 2000-02-18
PCT/EP2001/001673 WO2001060404A2 (en) 2000-02-18 2001-02-13 Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens

Publications (2)

Publication Number Publication Date
AU2001248314A1 true AU2001248314A1 (en) 2001-11-08
AU2001248314B2 AU2001248314B2 (en) 2004-08-19

Family

ID=8171051

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001248314A Ceased AU2001248314B2 (en) 2000-02-18 2001-02-13 Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens
AU4831401A Pending AU4831401A (en) 2000-02-18 2001-02-13 TH1 inducing natural adjuvant for heterologous antigens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU4831401A Pending AU4831401A (en) 2000-02-18 2001-02-13 TH1 inducing natural adjuvant for heterologous antigens

Country Status (7)

Country Link
US (1) US6936263B2 (en)
EP (1) EP1255562B1 (en)
AT (1) ATE383871T1 (en)
AU (2) AU2001248314B2 (en)
CA (1) CA2400495A1 (en)
DE (1) DE60132427D1 (en)
WO (1) WO2001060404A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248314B2 (en) * 2000-02-18 2004-08-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
JP2005517674A (en) * 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー Novel immunoconjugates useful for tumor treatment
EP1861426A4 (en) * 2005-02-08 2008-11-12 Queensland Inst Med Res Immunogenic molecules
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US7833776B2 (en) 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
ES2594102T3 (en) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutants by flagelin deletion and methods for its use
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
CN102482327B (en) * 2009-06-22 2014-10-29 财团法人卫生研究院 Lipidated tumor- associated antigens and immunotherapeutic compositions and related method
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (en) 2010-11-15 2015-11-11 Nat Health Research Institutes Lipidated polyepitope vaccines
CN113150171B (en) * 2021-04-25 2023-05-16 中国农业科学院兰州兽医研究所 African swine fever virus recombinant protein containing intramolecular adjuvant, expression vector and application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829616C2 (en) * 1988-09-01 1996-08-29 Behringwerke Ag Lipoprotein I (OMPI) from Pseudomonas aeruginosa
FR2708622B1 (en) * 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
ATE190657T1 (en) * 1994-12-16 2000-04-15 Chiron Behring Gmbh & Co IMMUNOGENIC HYBRID PROTEIN OPRF-OPRL AVAILABLE FROM MEMBRANE PROTEINS OF PSEUDOMONAS AERUGINOSA
AU6280596A (en) * 1995-06-15 1997-01-15 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides
US6638517B2 (en) * 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6607731B1 (en) * 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6537552B1 (en) * 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
AU2001248314B2 (en) * 2000-02-18 2004-08-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens

Similar Documents

Publication Publication Date Title
AU2001248314A1 (en) Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens
HUP0300099A3 (en) Vaccine for the treatment of artherosclerosis
IL159209A0 (en) Mutant forms of cholera holotoxin as an adjuvant
AU2002223504A1 (en) Heterologous expression of taxanes
AU2001258279A1 (en) Adjuvant for vaccines
HK1104319A1 (en) Methods for the production of 3-o-deactivated-4'-monophosphoryl lipid a (3d-mla)
SI2255826T1 (en) Neisserial vaccine compositions comprising a combination of antigens
AU2002348122A1 (en) Waterless hand cleaner containing natural essential oil
IL127661A0 (en) Induction of CTLs specific for natural antigens by cross-priming immunization
DE69405551D1 (en) 3-0-DEACYLATED MONOPHOSPHORYL LIPID A CONTAINING VACCINE COMPOSITIONS
HUP0001403A3 (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
HUP0300696A3 (en) Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha
EP1337149A4 (en) Vaccine immunotherapy for immune suppressed patients
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
HUP0200583A3 (en) A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
GB0123756D0 (en) A novel chaperone-type of adjuvant for vaccination - Basic 1
IL149614A0 (en) Novel use of antibodies as vaccines
HK1047034A1 (en) Use of cpg as an adjuvant for malaria vaccine
AU2001293891A1 (en) New combination for the treatment of asthma
AU7597501A (en) Method for immuno-detection of epitopes
AU2002366544A1 (en) Adjuvant formulations for bacterial and virus vaccines and method of making same
AU4621799A (en) Use of an amphipathic compound for providing an adjuvant to subunit vaccine
AU2001286775A1 (en) Adjuvant
EP1210364A4 (en) Vaccine antigens of moraxella